IL276534B2 - Methods for purifying serpin containing fusion proteins - Google Patents

Methods for purifying serpin containing fusion proteins

Info

Publication number
IL276534B2
IL276534B2 IL276534A IL27653420A IL276534B2 IL 276534 B2 IL276534 B2 IL 276534B2 IL 276534 A IL276534 A IL 276534A IL 27653420 A IL27653420 A IL 27653420A IL 276534 B2 IL276534 B2 IL 276534B2
Authority
IL
Israel
Prior art keywords
polypeptide
aat
fusion protein
seq
serpin
Prior art date
Application number
IL276534A
Other languages
English (en)
Hebrew (he)
Other versions
IL276534A (en
IL276534B1 (en
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of IL276534A publication Critical patent/IL276534A/en
Publication of IL276534B1 publication Critical patent/IL276534B1/en
Publication of IL276534B2 publication Critical patent/IL276534B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
IL276534A 2011-06-28 2012-06-28 Methods for purifying serpin containing fusion proteins IL276534B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US201261638168P 2012-04-25 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
IL276534A IL276534A (en) 2020-09-30
IL276534B1 IL276534B1 (en) 2025-07-01
IL276534B2 true IL276534B2 (en) 2025-11-01

Family

ID=47424806

Family Applications (3)

Application Number Title Priority Date Filing Date
IL276534A IL276534B2 (en) 2011-06-28 2012-06-28 Methods for purifying serpin containing fusion proteins
IL312872A IL312872A (en) 2011-06-28 2012-06-28 Methods for purifying fusion proteins containing serphin
IL230209A IL230209B (en) 2011-06-28 2013-12-26 Serpin fusion polypeptides and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL312872A IL312872A (en) 2011-06-28 2012-06-28 Methods for purifying fusion proteins containing serphin
IL230209A IL230209B (en) 2011-06-28 2013-12-26 Serpin fusion polypeptides and methods of use thereof

Country Status (28)

Country Link
US (8) US8980266B2 (enExample)
EP (2) EP3569243A1 (enExample)
JP (5) JP2014523900A (enExample)
KR (6) KR20220003656A (enExample)
CN (3) CN110551223A (enExample)
AU (4) AU2012275287B2 (enExample)
BR (1) BR112013033799A2 (enExample)
CA (2) CA2839619C (enExample)
CY (1) CY1122195T1 (enExample)
DK (1) DK2726092T3 (enExample)
ES (1) ES2746052T3 (enExample)
HR (1) HRP20191652T1 (enExample)
HU (1) HUE046156T2 (enExample)
IL (3) IL276534B2 (enExample)
IN (1) IN2013MN02441A (enExample)
LT (1) LT2726092T (enExample)
ME (1) ME03473B (enExample)
MX (2) MX381183B (enExample)
NZ (1) NZ744257A (enExample)
PL (1) PL2726092T3 (enExample)
PT (1) PT2726092T (enExample)
RS (1) RS59368B1 (enExample)
RU (4) RU2642310C2 (enExample)
SG (2) SG10201811256QA (enExample)
SI (1) SI2726092T1 (enExample)
SM (1) SMT201900520T1 (enExample)
UA (1) UA124083C2 (enExample)
WO (1) WO2013003641A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20220003656A (ko) 2011-06-28 2022-01-10 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN103946388A (zh) * 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
WO2015191892A2 (en) 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
CA3161989A1 (en) 2014-07-23 2016-01-28 Inova Diagnostics, Inc. Compositions and methods for the diagnosis of rheumatoid arthritis
SG11201703390SA (en) * 2014-10-27 2017-05-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
US12031144B2 (en) * 2017-03-29 2024-07-09 Cornell University Oxidation-resistant AAT gene therapy
PL3657946T3 (pl) 2017-07-27 2025-03-31 The Regents Of The University Of Michigan Inhibitor aktywatora plazminogenu-1 (pai-1) i sposób jego zastosowania
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
EP4321220B1 (en) 2017-12-01 2025-10-29 CSL Behring LLC A1at for treating acute graft versus host disease after hematopoeitic cell transplantation
KR20210111245A (ko) * 2018-10-29 2021-09-10 스핀 테라퓨틱스, 엘엘씨 알파-1-항트립신 장애들을 위한 조성물들 및 방법들
EP3986920B1 (en) 2019-06-24 2025-04-16 Universität Stuttgart Tnfr2 agonists with improved stability
EP4007751A4 (en) * 2019-08-01 2023-07-05 Serplus Technology LLC OXIDATION RESISTANT SERPINES
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
CA3206022A1 (en) * 2021-01-26 2022-08-04 Traian Sulea Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
US20250049898A1 (en) * 2021-12-22 2025-02-13 The Regents Of The University Of California Compositions and methods for wound healing
IL316983A (en) 2022-05-16 2025-01-01 Sanofi Aatd Inc Effective dosage of recombinant SERPIN-FC fusion protein for use in a method of treating AAT deficiency in a subject
CN115466323B (zh) * 2022-09-13 2025-07-01 宁波博睿瀚达生物科技有限公司 一种分离分泌性白细胞蛋白酶抑制因子的方法
EP4483951A1 (en) * 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025083294A2 (en) 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP3370324B2 (ja) 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2364471A1 (en) 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
WO2001040249A1 (en) 1999-12-01 2001-06-07 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
MXPA03004017A (es) * 2000-11-08 2004-02-12 Prometic Biosciences Inc Metodo para el tratamiento de inflamacion.
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2430973A1 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
WO2002076489A1 (en) * 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
KR101323411B1 (ko) 2004-08-03 2013-10-30 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
CA2578613A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006113665A2 (en) * 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
JP4067557B2 (ja) 2005-06-03 2008-03-26 持田製薬株式会社 抗ｃｄ１４抗体融合蛋白質
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
EP1926747A1 (en) 2005-08-12 2008-06-04 Schering Corporation Mcp1 fusions
ES2839549T3 (es) * 2005-11-23 2021-07-05 Acceleron Pharma Inc Antagonistas de activina-ActRIIa de utilización en la estimulación del crecimiento óseo
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2007117440A2 (en) 2006-03-30 2007-10-18 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
DK2662449T3 (en) * 2007-05-30 2017-05-15 Postech Academy-Industry- Found immunoglobulin fusion proteins
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
US8598315B2 (en) * 2007-10-02 2013-12-03 Research Foundation Of City University Of New York Protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
ES2523043T3 (es) * 2008-07-23 2014-11-20 Hanmi Science Co., Ltd. Un complejo polipeptídico que comprende un polímero no peptidílico que tiene tres extremos funcionales
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
KR20110104032A (ko) 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
US9012606B2 (en) 2009-04-22 2015-04-21 Alteogen, Inc. In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
BR112012000830B8 (pt) 2009-07-08 2022-11-22 Univ Missouri Óleo produzido por uma população de sementes de soja e método de produção de uma planta de soja
PL2498799T3 (pl) 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
WO2012003290A2 (en) 2010-06-30 2012-01-05 University Of Maryland, Baltimore Dental composites comprising nanoparticles of amorphous calcium phosphate
RS55906B1 (sr) 2010-12-23 2017-09-29 Janssen Biotech Inc Mutanti fc antitela koji su otporni na aktivnu proteazu
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
CA2839917A1 (en) * 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
CN103946388A (zh) 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR20220003656A (ko) 2011-06-28 2022-01-10 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US20140051834A1 (en) 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
MX2015000681A (es) 2012-08-02 2015-04-10 Hoffmann La Roche Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas.
EP2929045B1 (en) 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
WO2015191892A2 (en) * 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KITA, SHUNBUN, ET AL., COMPETITIVE BINDING OF MUSCLIN TO NATRIURETIC PEPTIDE RECEPTOR 3 WITH ATRIAL NATRIURETIC PEPTIDE., 31 December 2009 (2009-12-31) *

Also Published As

Publication number Publication date
SMT201900520T1 (it) 2019-11-13
AU2019202904A1 (en) 2019-05-16
US20210002352A1 (en) 2021-01-07
ES2746052T3 (es) 2020-03-04
CA2839619C (en) 2021-11-16
EP2726092A2 (en) 2014-05-07
CN110066340A (zh) 2019-07-30
US8980266B2 (en) 2015-03-17
NZ619023A (en) 2015-07-31
AU2012275287B2 (en) 2017-10-05
HUE046156T2 (hu) 2020-02-28
KR20210032558A (ko) 2021-03-24
EP2726092A4 (en) 2015-08-19
CN103917563A (zh) 2014-07-09
UA124083C2 (uk) 2021-07-21
MX2013015323A (es) 2014-06-23
IL312872A (en) 2024-07-01
HRP20191652T1 (hr) 2019-12-13
KR20230114318A (ko) 2023-08-01
US20250011394A1 (en) 2025-01-09
IN2013MN02441A (enExample) 2015-06-12
AU2017279724B2 (en) 2019-03-14
KR102231139B1 (ko) 2021-03-24
AU2021202131B2 (en) 2023-01-12
CY1122195T1 (el) 2020-11-25
US20210024613A1 (en) 2021-01-28
WO2013003641A2 (en) 2013-01-03
MX356517B (es) 2018-06-01
US10730929B2 (en) 2020-08-04
US9920109B2 (en) 2018-03-20
RU2017145308A3 (enExample) 2019-02-18
AU2021202131A1 (en) 2021-05-06
NZ744257A (en) 2022-10-28
IL276534A (en) 2020-09-30
RU2728861C1 (ru) 2020-07-31
IL230209B (en) 2020-08-31
RU2727452C1 (ru) 2020-07-21
BR112013033799A2 (pt) 2017-02-14
CN110551223A (zh) 2019-12-10
US11827691B2 (en) 2023-11-28
LT2726092T (lt) 2019-10-10
JP2018008956A (ja) 2018-01-18
RS59368B1 (sr) 2019-11-29
KR20220003656A (ko) 2022-01-10
CA3132298A1 (en) 2013-01-03
US20130011398A1 (en) 2013-01-10
MX381183B (es) 2025-03-12
IL276534B1 (en) 2025-07-01
KR102084944B1 (ko) 2020-04-17
US20180179264A1 (en) 2018-06-28
PT2726092T (pt) 2019-10-08
KR20140054000A (ko) 2014-05-08
JP2024138397A (ja) 2024-10-08
JP2022109968A (ja) 2022-07-28
RU2017145308A (ru) 2019-02-18
US20150147325A1 (en) 2015-05-28
US20130330769A1 (en) 2013-12-12
US11965017B2 (en) 2024-04-23
RU2642310C2 (ru) 2018-01-24
KR20200027041A (ko) 2020-03-11
EP3569243A1 (en) 2019-11-20
AU2019202904B2 (en) 2021-01-07
RU2698655C2 (ru) 2019-08-28
KR20250012200A (ko) 2025-01-23
ME03473B (me) 2020-01-20
RU2014102583A (ru) 2015-08-10
RU2020124172A (ru) 2022-01-21
SG10201601621PA (en) 2016-04-28
SI2726092T1 (sl) 2019-11-29
KR102756547B1 (ko) 2025-01-21
SG10201811256QA (en) 2019-01-30
JP6674604B2 (ja) 2020-04-01
US20200102371A1 (en) 2020-04-02
JP2014523900A (ja) 2014-09-18
JP2020078325A (ja) 2020-05-28
PL2726092T3 (pl) 2019-11-29
CN110066340B (zh) 2024-06-25
AU2017279724A1 (en) 2018-01-25
US10723785B2 (en) 2020-07-28
WO2013003641A3 (en) 2013-03-21
DK2726092T3 (da) 2019-09-30
EP2726092B1 (en) 2019-06-19
AU2012275287A1 (en) 2014-01-16
CA2839619A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
AU2021202131B2 (en) Serpin fusion polypeptides and methods of use thereof
US11046752B2 (en) Serpin fusion polypeptides and methods of use thereof
IL308589A (en) Serpin fusion polypeptides and methods of use thereof
HK40017627A (en) Serpin fusion polypeptides and methods of use thereof
HK1197544A (en) Serpin fusion polypeptides and methods of use thereof
HK1197544B (en) Serpin fusion polypeptides and methods of use thereof
NZ619023B2 (en) Serpin fusion polypeptides and methods of use thereof
NZ727846B2 (en) Serpin fusion polypeptides and methods of use thereof